Latest Point Therapeutics Inc. Stories
Point Therapeutics Achieves Interim Tumor Response Criteria in Phase 2 Non-Small Cell Lung Cancer Study; Company Advances Talabostat to Second Stage of Study
Point Therapeutics, Inc. (NASDAQ:POTP) today announced that it has successfully completed the first stage of the Company's Phase 2 clinical study in Stage IIIB/IV non-small cell lung cancer.
Word of the Day
- Emitting flashes of light; glittering.
The word 'coruscant' comes from a Latin word meaning 'to flash' or 'to sparkle'.